Pharmaceutical approaches to weight management: behavioural mechanisms of action



Roberts, Carl A ORCID: 0000-0003-4275-601X, Christiansen, Paul and Halford, Jason CG ORCID: 0000-0003-1629-3189
(2019) Pharmaceutical approaches to weight management: behavioural mechanisms of action. CURRENT OPINION IN PHYSIOLOGY, 12. pp. 26-32.

[img] Text
1-s2.0-S2468867319300707-main.pdf - Author Accepted Manuscript

Download (483kB) | Preview

Abstract

Pharmacotherapy as an adjunct to behaviour modification, may provide an effective addition to individual weight management plans in specialised weight management services. There are four FDA approved centrally acting weight-loss drugs (liraglutide, bupropion/naltrexone, lorcaserin, phentermine/topiramate), and several additional candidate drugs yet to receive approval. Each drug has a distinct pharmacological mechanism of action, and presumably will support eating behaviour modification in different ways. Here, we assess to what extent behavioural mechanisms of action have been characterised. We recommend a methodological platform to be introduced pre-approval in order to achieve principal objectives of phase II and III trials (demonstrate efficacy), and afford stratification of responders to treatment, by behavioural and neurophysiological response.

Item Type: Article
Depositing User: Symplectic Admin
Date Deposited: 24 May 2019 11:56
Last Modified: 19 Jan 2023 00:43
DOI: 10.1016/j.cophys.2019.04.017
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3042783